Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Innovative Strategies: Targeting Subtypes in Metastatic Breast CancerMark D Pegram, Yu Zong, Clinton Yam, et al.
Plos One|July 27, 2021
Single-cell immunoblotting resolves estrogen receptor-α isoforms in breast cancerJohn J Kim, Wenchuan Liang, Chi-Chih Kang, et al.
Journal of Experimental Therapeutics & Oncology|May 3, 2003
Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN LinkerCarl W Gilbert, Eleanor B McGowan, Gerald B Seery, et al.
Journal of the National Cancer Institute|May 20, 2004
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancerMark D Pegram, Gottfried E Konecny, Carminda O'Callaghan, et al.
Cancer Treatment Reviews|March 9, 2023
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature reviewVolkmar Müller, Rupert Bartsch, Nancy U Lin, et al.
NPJ Precision Oncology|June 7, 2018
Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolutionChi-Chih Kang, Toby M Ward, Jessica Bockhorn, et al.
Journal for Immunotherapy of Cancer|January 7, 2022
Role of Fcγ receptors in HER2-targeted breast cancer therapyAntonino Musolino, William J Gradishar, Hope S Rugo, et al.
Advanced Materials (Deerfield Beach, Fla.)|November 17, 2015
Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western BlottingTodd A Duncombe, Chi-Chih Kang, Santanu Maity, et al.
Breast Cancer Research and Treatment|April 2, 2013
The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patientsJudith Hurley, Isildinha M Reis, Steven E Rodgers, et al.
Breast Cancer Research and Treatment|October 24, 2012
PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cellsAnna-Maria Jegg, Toby M Ward, Elizabeth Iorns, et al.
Pageof 6